U.S. markets open in 4 hours 49 minutes
  • S&P Futures

    3,293.00
    +29.50 (+0.90%)
     
  • Dow Futures

    26,610.00
    +201.00 (+0.76%)
     
  • Nasdaq Futures

    11,256.50
    +123.75 (+1.11%)
     
  • Russell 2000 Futures

    1,549.90
    +10.70 (+0.70%)
     
  • Crude Oil

    37.23
    -0.16 (-0.43%)
     
  • Gold

    1,879.30
    +0.10 (+0.01%)
     
  • Silver

    23.30
    -0.06 (-0.25%)
     
  • EUR/USD

    1.1737
    -0.0012 (-0.11%)
     
  • 10-Yr Bond

    0.7810
    0.0000 (0.00%)
     
  • Vix

    38.90
    +5.55 (+16.64%)
     
  • GBP/USD

    1.2991
    +0.0003 (+0.03%)
     
  • USD/JPY

    104.2550
    -0.0460 (-0.04%)
     
  • BTC-USD

    13,163.39
    +8.02 (+0.06%)
     
  • CMC Crypto 200

    260.38
    -12.31 (-4.52%)
     
  • FTSE 100

    5,594.79
    +11.99 (+0.21%)
     
  • Nikkei 225

    23,331.94
    -86.57 (-0.37%)
     

New Strong Sell Stocks for March 27th

Zacks Equity Research
Investors need to pay close attention to Intra-Cellular Therapies (ITCI) stock based on the movements in the options market lately.
Investors need to pay close attention to Intra-Cellular Therapies (ITCI) stock based on the movements in the options market lately.

Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:

Advanced Energy Industries, Inc. AEIS is a manufacturer of power conversion, measurement and control solutions that transform electrical power into various usable forms. The Zacks Consensus Estimate for its current year earnings has been revised 1.3% downward over the last 30 days.

AdvanSix Inc. ASIX is a manufacturer and seller of polymer resins. The Zacks Consensus Estimate for its current year earnings has been revised 10.9% downward over the last 30 days.

Anheuser-Busch InBev SA/NV BUD is a producer and distributor of beer, alcoholic beverages, and soft drinks. The Zacks Consensus Estimate for its current year earnings has been revised 0.4% downward over the last 30 days.

BioMarin Pharmaceutical Inc. BMRN is a developer of therapies for life-threatening rare diseases and medical conditions. The Zacks Consensus Estimate for its current year earnings has been revised 13.1% downward over the last 30 days.

Champions Oncology, Inc. CSBR is a developer of technology solutions used in personalizing the development and use of oncology drugs. The Zacks Consensus Estimate for its current year earnings has been revised 8.3% downward over the last 30 days.

View the entire Zacks Rank #5 List.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Anheuser-Busch InBev SA/NV (BUD) : Free Stock Analysis Report
 
BioMarin Pharmaceutical Inc. (BMRN) : Free Stock Analysis Report
 
Champions Oncology, Inc. (CSBR) : Free Stock Analysis Report
 
Advanced Energy Industries, Inc. (AEIS) : Free Stock Analysis Report
 
AdvanSix Inc. (ASIX) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research